Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?

Research output: Contribution to journalArticlepeer-review


Despite progress in the therapeutic management of idiopathic pulmonary fibrosis (IPF) in the last decade, prognosis remains poor (1). This is particularly true of patients with severe disease, with 3-year mortality predicted at 76.8% for patients with advanced disease (2). Therapeutic trials in IPF typically exclude such patients which can subsequently have a significant impact on drug availability in the clinical setting. There is a desperate unmet need for treatment options in this advanced disease cohort.

Bibliographical metadata

Original languageEnglish
JournalJournal of Thoracic Disease
Publication statusPublished - 1 Feb 2019